Detalhe da pesquisa
1.
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.
Clin Infect Dis
; 74(1): 95-104, 2022 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33693561
2.
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Clin Infect Dis
; 72(7): 1247-1250, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32597466
3.
Novel method to quantify phenotypic markers of HIV-associated neurocognitive disorder in a murine SCID model.
J Neurovirol
; 26(6): 838-845, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32901392
4.
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.
J Neuroinflammation
; 16(1): 182, 2019 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31561750
5.
Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
PLoS Pathog
; 13(12): e1006740, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29267399
6.
Host SAMHD1 protein restricts endogenous reverse transcription of HIV-1 in nondividing macrophages.
Retrovirology
; 15(1): 69, 2018 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30316304
7.
Synthesis and antiviral evaluation of 2',2',3',3'-tetrafluoro nucleoside analogs.
Tetrahedron Lett
; 58(7): 642-644, 2017 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28163339
8.
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Neurobiol Dis
; 92(Pt B): 137-43, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26851503
9.
Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
Antimicrob Agents Chemother
; 58(4): 1977-86, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24419350
10.
Honokiol hexafluoro confers reversal of neuropathological markers of HIV infection in a murine SCID model.
Neurotherapeutics
; 21(2): e00329, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38388224
11.
Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages.
Antimicrob Agents Chemother
; 57(3): 1262-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23263005
12.
Readily available drugs and other interventions to potentially improve the efficacy of immune checkpoint blockade in cancer.
Front Immunol
; 14: 1281744, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299150
13.
The comorbidity of depression and neurocognitive disorder in persons with HIV infection: call for investigation and treatment.
Front Cell Neurosci
; 17: 1130938, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37206666
14.
Abundant non-canonical dUTP found in primary human macrophages drives its frequent incorporation by HIV-1 reverse transcriptase.
J Biol Chem
; 286(28): 25047-55, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21454906
15.
Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.
Front Immunol
; 13: 1033672, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36569952
16.
A Rationale and Approach to the Development of Specific Treatments for HIV Associated Neurocognitive Impairment.
Microorganisms
; 10(11)2022 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36422314
17.
Cognitively Based Compassion Training for HIV Immune Nonresponders-An Attention-Placebo Randomized Controlled Trial.
J Acquir Immune Defic Syndr
; 89(3): 340-348, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879006
18.
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.
J Biol Chem
; 285(50): 39380-91, 2010 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20924117
19.
Targeting Macrophage Dysregulation for Viral Infections: Novel Targets for Immunomodulators.
Front Immunol
; 12: 768695, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34790202
20.
The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
Front Immunol
; 12: 720697, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34531866